Some investigational Alzheimer’s disease therapies are more effective when paired with a treatment geared toward improving drainage of fluid and debris from the brain, according to a study in mice.
Experimental Alzheimer’s drugs have shown little success in slowing declines in memory and thinking, leaving scientists searching for explanations.
The new findings in the journal
Nature, however, suggest that the brain’s drainage system known as the meningeal lymphatics plays a pivotal but underappreciated role in neurodegenerative disease, and that repairing faulty drains could be a key to unlocking the potential of certain Alzheimer’s therapies.
“The lymphatic system is how the garbage is cleaned out of the brain. If it’s not working, everything gets gummed up.
PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer’s Disease Pathologies
PureTech Announces
Preclinical research suggests that restoring lymphatic flow in the brain has the potential to address a range of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases, and associated neuroinflammation
Additionally, research found that improving lymphatic flow could enhance the efficacy of antibody therapies against aberrant proteins, potentially opening a new avenue for disease management
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the publication of preclinical research in
Nueva vía para mejorar la terapia del Alzheimer infosalus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infosalus.com Daily Mail and Mail on Sunday newspapers.
New preclinical research, published in Nature, suggests a new avenue for Alzheimer’s disease (AD) treatment, through restoring lymphatic flow in the brain
Impaired drainage also may play a role in Alzheimer’s in people
The drainage network in a mouse’s brain is outlined in blue and green, and dotted with clumps of the Alzheimer’s protein amyloid beta (red). Researchers at Washington University School of Medicine in St. Louis have found that improving the function of the network, known as the meningeal lymphatics, can make certain experimental Alzheimer’s therapies more effective in mice. (Image: Sandro Da Mesquita)
April 28, 2021 SHARE
Experimental Alzheimer’s drugs have shown little success in slowing declines in memory and thinking, leaving scientists searching for explanations. But new research in mice has shown that some investigational Alzheimer’s therapies are more effective when paired with a treatment geared toward improving drainage of fluid and debris from the brain, according to a study led by researchers at Washington University School of Medicine in St. Louis.